| Dapagliflozin in Patients with Chronic Kidney Disease. WDC Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou ... N Engl J Med 383 (15), 1436-1446, 2020 | 3664* | 2020 |
| Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption DB Simon, Y Lu, KA Choate, H Velazquez, E Al-Sabban, M Praga, ... Science 285 (5424), 103-106, 1999 | 1345 | 1999 |
| Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of … GK Bertsias, M Tektonidou, Z Amoura, M Aringer, I Bajema, JHM Berden, ... Annals of the rheumatic diseases 71 (11), 1771-1782, 2012 | 1244 | 2012 |
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease N Engl J Med 369 (26), 2492-503, 2013 | 1049* | 2013 |
| 2019 update of the joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the … A Fanouriakis, M Kostopoulou, K Cheema, HJ Anders, M Aringer, ... Annals of the rheumatic diseases 79 (6), 713-723, 2020 | 708 | 2020 |
| Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis VD D'Agati, A Chagnac, AP De Vries, M Levi, E Porrini, ... Nature Reviews Nephrology 12 (8), 453-471, 2016 | 602 | 2016 |
| Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. SO Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G ... N Engl J Med 377 (20), 1930-1942, 2017 | 576* | 2017 |
| Acute interstitial nephritis M Praga, E González Kidney international 77 (11), 956-961, 2010 | 568 | 2010 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial HJL Heerspink, HH Parving, DL Andress, G Bakris, R Correa-Rotter, ... The Lancet 393 (10184), 1937-1947, 2019 | 505 | 2019 |
| Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy M Praga, E Hernández, JC Herrero, E Morales, Y Revilla, ... Kidney international 58 (5), 2111-2118, 2000 | 495 | 2000 |
| Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis E González, E Gutiérrez, C Galeano, C Chevia, P de Sequera, C Bernis, ... Kidney international 73 (8), 940-946, 2008 | 473 | 2008 |
| Clinical features and long‐term outcome of obesity‐associated focal segmental glomerulosclerosis M Praga, E Hernández, E Morales, AP Campos, MA Valero, MA Martínez, ... Nephrology Dialysis Transplantation 16 (9), 1790-1798, 2001 | 461 | 2001 |
| Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies E Morales, MA Valero, M León, E Hernández, M Praga American Journal of Kidney Diseases 41 (2), 319-327, 2003 | 459 | 2003 |
| Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial M Praga, E Gutiérrez, E Gonzalez, E Morales, E Hernández Journal of the American Society of Nephrology 14 (6), 1578-1583, 2003 | 453 | 2003 |
| Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments R Coppo, S Troyanov, S Bellur, D Cattran, HT Cook, J Feehally, ... Kidney international 86 (4), 828-836, 2014 | 442 | 2014 |
| Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy N Polanco, E Gutiérrez, A Covarsí, F Ariza, A Carreño, A Vigil, J Baltar, ... Journal of the American Society of Nephrology 21 (4), 697-704, 2010 | 442 | 2010 |
| Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease APJ De Vries, P Ruggenenti, XZ Ruan, M Praga, JM Cruzado, IM Bajema, ... The lancet Diabetes & endocrinology 2 (5), 417-426, 2014 | 438 | 2014 |
| Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial M Praga, V Barrio, GF Juárez, J Luno Kidney international 71 (9), 924-930, 2007 | 379 | 2007 |
| Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial BC Fellström, J Barratt, H Cook, R Coppo, J Feehally, JW de Fijter, ... The Lancet 389 (10084), 2117-2127, 2017 | 355 | 2017 |
| Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: workshop recommendations DC Cattran, E Alexopoulos, P Heering, PF Hoyer, A Johnston, A Meyrier, ... Kidney international 72 (12), 1429-1447, 2007 | 335 | 2007 |
